Form 4: Galectin Therapeutics Director James Czirr Significantly Boosts Stake by Over 300,000 Shares Through Option Exercises and Dividend Reinvestment

Galectin Therapeutics Inc. Director and 10% Owner James C. Czirr significantly increased his direct beneficial ownership of common stock by over 300,000 shares through the exercise of stock options and receipt of dividend shares, despite gifting 20,000 shares to relatives.

Summary

• James C. Czirr, a Director and 10% Owner of Galectin Therapeutics Inc. (GALT), reported several transactions in the company's common stock.
• On February 3 and 4, 2025, Mr. Czirr gifted a total of 20,000 shares of common stock to relatives, with no consideration received.
• On March 31, 2025, Mr. Czirr acquired 1,000 shares of common stock at a price of $6.00 per share, which were received in satisfaction of $6,000 in dividends due on his Series A Convertible Preferred Stock.
• On June 6, 2025, Mr. Czirr exercised multiple stock options, acquiring a total of 323,125 shares of common stock at exercise prices ranging from $0.89 to $4.72.
• Following these transactions, Mr. Czirr's direct beneficial ownership of common stock increased from 731,416 shares (as of February 3, 2025, before the first reported gift) to 1,045,541 shares as of June 6, 2025.
• All stock options reported in Table II were exercised on June 6, 2025, and expired on June 7, 2025, resulting in zero derivative securities beneficially owned thereafter.

Sentiment

Score: 8

Explanation: The sentiment is largely positive due to a substantial increase in direct beneficial ownership by a key insider (Director and 10% Owner) through option exercises, which typically signals confidence in the company's future prospects. While there were gifts of shares, the net effect is a significant increase in holdings.

Positives

• Director James C. Czirr significantly increased his direct beneficial ownership of common stock by 314,125 shares, indicating confidence in the company.
• The exercise of 323,125 stock options suggests a positive outlook from a key insider, as these options were exercisable and converted into common stock.
• The receipt of 1,000 shares of common stock as a dividend payment demonstrates the company's option to pay dividends in stock, which can conserve cash.

Negatives

• James C. Czirr disposed of 20,000 shares of common stock through gifts to relatives, which reduces his direct ownership, although this is a non-sale transaction.

Risks

• The document itself, being a Form 4, does not explicitly state risks. However, the exercise of options close to their expiration date (June 6, 2025, with expiration on June 7, 2025) could imply a need to act before expiry rather than a strong new investment decision, though it still results in increased ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The document includes the signature of James C. Czirr, Individually, dated 06/11/2025, confirming the accuracy of the reported transactions.

Industry Context

This Form 4 filing details insider transactions and does not provide broader industry context or trends. It focuses solely on the changes in beneficial ownership for a specific insider at Galectin Therapeutics Inc.

Related Party Transactions

• James C. Czirr transferred 20,000 shares of common stock by gift to relatives, as explicitly stated in the filing.

Stakeholder Impact

• Shareholders may view the significant increase in a key insider's direct ownership as a positive signal of management's confidence in the company's future performance and value.
• The exercise of options by a director could be interpreted as a belief that the current stock price is favorable or that future appreciation is expected.

Next Steps

• This Form 4 filing does not outline any specific future actions, events, or milestones for the company or the reporting person beyond the reported transactions.

Key Dates

Recommendation

Keywords

Galectin Therapeutics, GALT, SEC Form 4, Insider Trading, Stock Option Exercise, Beneficial Ownership, Director Stock Transactions, Dividend Reinvestment, Equity Ownership